Compare TMCI & CDXS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TMCI | CDXS |
|---|---|---|
| Founded | 2014 | 2002 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Electromedical & Electrotherapeutic Apparatus | Major Chemicals |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 144.0M | 141.8M |
| IPO Year | 2021 | 2010 |
| Metric | TMCI | CDXS |
|---|---|---|
| Price | $1.84 | $1.21 |
| Analyst Decision | Hold | |
| Analyst Count | 5 | 0 |
| Target Price | ★ $4.21 | N/A |
| AVG Volume (30 Days) | 617.2K | ★ 1.2M |
| Earning Date | 02-27-2026 | 02-27-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $218,879,000.00 | $52,932,000.00 |
| Revenue This Year | $3.30 | $15.64 |
| Revenue Next Year | N/A | $5.23 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 7.90 | N/A |
| 52 Week Low | $1.86 | $1.12 |
| 52 Week High | $10.30 | $4.46 |
| Indicator | TMCI | CDXS |
|---|---|---|
| Relative Strength Index (RSI) | 28.79 | 36.19 |
| Support Level | $2.02 | $1.12 |
| Resistance Level | $2.31 | $1.28 |
| Average True Range (ATR) | 0.16 | 0.11 |
| MACD | -0.03 | -0.01 |
| Stochastic Oscillator | 7.88 | 23.61 |
Treace Medical Concepts Inc is a commercial-stage orthopaedic medical device company. It is focused on advancing the standard of care for the surgical management of bunion deformities. The company's patented Lapiplasty 3D Bunion Correction procedure is designed to reproducibly correct all planes of the bunion deformity and address the root cause of the bunion, while allowing patients to return to their active lives quickly. The Company operates and manages its business as one segment, which is the business of designing, manufacturing, and marketing medical devices for physicians, surgeons, ambulatory surgery centers and hospitals.
Codexis Inc is a provider of enzymatic solutions for efficient and scalable therapeutics manufacturing that leverages its proprietary CodeEvolver technology platform to discover, develop, and enhance novel, high-performance enzymes. Codexis enzymes solve challenges associated with small molecule pharmaceuticals manufacturing and nucleic acid synthesis. The Company is currently developing its proprietary ECO Synthesis manufacturing platform to enable the scaled manufacture of RNAi therapeutics through an enzymatic route. Codexis' enzymes can drive improvements such as higher yields, reduced energy usage and waste generation, improved efficiency in manufacturing and greater sensitivity in genomic and diagnostic applications. Geographically, it derives maximum revenue from the Americas.